Billions in Deals Reshaping the Cell and Gene Therapy Industry, reports Kalorama Information
The report is released in two installments, with the first part available now, covering deals through Q4 2024. The second installment, included with purchase, will be released in Fall 2025 and cover activity through Q3 2025.
'Many categories of deals, such as collaborations, distribution/co-marketing, and manufacturing/supply chain, have shown a long-term pattern of growth,' said Justin Saeks, senior market analyst at Kalorama Information. 'And there's reason for optimism regarding continued investments. Cell and gene therapy-related companies have continued to receive huge amounts of investment.'
Key Insights from the Report:
Over 2,000 CGT-related deals analyzed, with quarterly trends tracked from Q1 2021 to Q4 2024
Despite a tighter funding environment, 2024 investment reached an estimated $39 billion, with a sharp Q4 uptick
Top dealmakers include Astellas, Bristol Myers Squibb, Ginkgo Bioworks, Charles River, and Eli Lilly
Deal types covered: VC/PE, IPO/SPAC, licensing, tech transfer, acquisitions, supply chain partnerships, and more
Global perspective includes detailed breakdowns by region — North America, Europe, and APAC
Why This Matters Now
The CGT market is maturing fast, with fluctuating investment trends, growing deal diversity, and strategic partnerships becoming essential to survival. In 2023 and 2024, firms faced a contraction in available capital — from $73 billion in 2021 down to $35 billion in 2023 — yet collaborative and manufacturing partnerships have been on the rise. This suggests that dealmaking is evolving, not disappearing.
Who Should Purchase and Read This Report
This report is essential for:
Biotech and pharma execs seeking M&A or licensing opportunities
VC/PE investors tracking funding cycles and active biotech targets
Strategic planners and BD professionals looking to benchmark activity
Consultants, CROs, and CMOs aligning services with market needs
Regulatory and policy advisors assessing funding shifts and regional dynamics
Strategic Use Cases
Identify high-activity players and ideal partners for collaboration or acquisition
Benchmark funding rounds and valuations for startups or expanding companies
Inform R&D focus by tracking which technologies (e.g., CRISPR, AAV) are attracting deals
Support global expansion using regional deal patterns and emerging market trends
Strengthen regulatory preparedness by understanding the impact of policy shifts on financing
Companion Report Available
This report pairs with Kalorama's Cell and Gene Therapy Market Dynamics by Disease Type: Development, Trends, and Forecasts, 2024–2030 (4th Edition) — offering disease-area breakdowns of the CGT landscape in oncology, neurology, musculoskeletal, and beyond.
Get the Report
Download or purchase the report here:Cell and Gene Therapy Market Deals: Investments, M&As, and Partnerships, 2021–2025 (3rd Edition)
Explore the companion report:Cell and Gene Therapy Market Dynamics by Disease Type, 2024–2030 (4th Edition)
About Kalorama InformationKalorama Information, part of Science and Medicine Group, is a trusted source of market research in the life sciences. With a focus on in vitro diagnostics, biotechnology, and medical devices, Kalorama reports are used by top healthcare companies, government agencies, and investment firms worldwide.
For purchase or custom consultation, contact:Sheri DavieKalorama Information Sales Directorsheri.davie@scienceandmedicinegroup.com
For media inquiries please contact:Alisa AlvichMarketing Directoralisa.alvich@scienceandmedicinegroup.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
8 hours ago
- The Star
No plans yet to penalise China for buying Russian oil
FILE PHOTO: A view shows a pressure gauge near oil pump jacks outside Almetyevsk, in the Republic of Tatarstan, Russia July 14, 2025. REUTERS/Stringer/File Photo WASHINGTON: US president Donald Trump says he does not immediately need to consider retaliatory tariffs on countries such as China for buying Russian oil but might have to 'in two or three weeks'. Trump has threatened sanctions on Moscow and secondary sanctions on countries that buy its oil if no moves are made to end the war in Ukraine. China and India are the top two buyers of Russian oil. The president last week imposed an additional 25% tariff on Indian goods, citing its continued imports of Russian oil. However, Trump has not taken similar action against China. He was asked by Fox News' Sean Hannity if he was now considering such action against Beijing after he and Russian President Vladimir Putin failed to produce an agreement to resolve or pause Moscow's war in Ukraine. 'Well, because of what happened today, I think I don't have to think about that,' Trump said after his summit with Putin in Alaska. 'Now, I may have to think about it in two weeks or three weeks or something, but we don't have to think about that right now. I think, you know, the meeting went very well.' Chinese President Xi Jinping's slowing economy will suffer if Trump follows through on a promise to ramp up Russia-related sanctions and tariffs. — Reuters
Malaysian Reserve
2 days ago
- Malaysian Reserve
Siemba Named a Sample Vendor in Three 2025 Gartner® Hype Cycle™ Reports for the Second Year in a Row
ATLANTA, Aug. 16, 2025 /PRNewswire/ — Siemba, a leading provider of Penetration Testing as a Service (PTaaS) and Continuous Threat Exposure Management (CTEM), announced today that it has been recognized as a Sample Vendor in the 2025 Gartner® Hype Cycle™ for Application Security, Security Operations, and Everything as a Service (XaaS) reports. This marks the second consecutive year Siemba has been included in all three Hype Cycle reports. Siemba believes this reinforces its growing role in shaping the future of offensive security. The Gartner Hype Cycle reports provide a perspective on the maturity and adoption of emerging technologies. For cybersecurity decision-makers, these reports serve as strategic guides to evaluate which innovations can address real-world risks and drive long-term security improvements. In all three reports, Siemba was identified as a Sample Vendor for Penetration Testing as a Service (PTaaS). Siemba believes that its scalable, platform-driven approach to offensive security will make it easier for organizations to secure their data and assets. 'We are proud to be recognized for the second consecutive year across three Gartner Hype Cycle reports. We believe this is a strong validation of our thesis that continuous validation and visibility are critical to modern cybersecurity,' said Kannan Udayarajan, Founder and CEO of Siemba. 'We're proud that our Full Funnel Offensive Security platform is helping organizations find, prioritize, and remediate risks faster—at the pace of their business.' The 2025 Gartner Hype Cycle for Application Security notes: 'Cybersecurity leaders must take advantage of the underlying trends in the application security space to onboard the most appropriate innovations at the optimal time for their organizational maturity.'(Source: Gartner, Hype Cycle for Application Security, 2025. Dionisio Zumerle, 22 July 2025) Gartner states 'PTaaS enables organizations to elevate their security posture with continuous assessments that integrate validation earlier in the software development life cycle as compared with traditional pentesting efforts. It gives access to real-time findings delivered through a platform, which accelerates remediation and improves collaboration efforts.' Siemba's AI driven platform combines External Attack Surface Mapping, Dynamic Application Security Testing (DAST), Automated Vulnerability Assessments, and Penetration Testing as a Service, helping enterprises operationalize CTEM programs at scale. To learn more or download the 2025 Hype Cycle for Security Operations, visit : Gartner Disclaimer Gartner, Hype Cycle for Application Security, 2025, By Dionisio Zumerle, 22 July 2025Gartner, Hype Cycle for Security Operations, 2025, By Jonathan Nunez, Darren Livingstone, 23 June 2025Gartner, Hype Cycle for XaaS, 2025, By Jason Donham, 28 July 2025 GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, HYPE CYCLE is a registered trademark of Gartner, Inc. and/or its affiliates and is used herein with permission. All rights reserved. Gartner does not endorse any vendor, product or service depicted in our research publications and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. About Siemba Siemba's outcome-driven Full Funnel Offensive Security model brings together Penetration Testing as a Service (PTaaS), Autonomous DAST (Dynamic Application Security Testing), Vulnerability Assessments, and External Attack Surface Mapping on one unified AI-driven platform. The platform delivers actionable data and insights enabling visibility, speed, scalability, and efficiency in Continuous Threat Exposure Management (CTEM). Enterprises, global systems integrators, government agencies and growing companies leverage Siemba to establish CTEM programs, map assets, launch and schedule autonomous assessments, conduct manual penetration testing and autonomously gather strategic threat and efficiency insights to maximize Return on Mitigation, without requiring extensive hacking knowledge or human intervention. The platform provides one-click security-framework-aligned reports, attack scoring, prioritized lists of findings with suggested remediation actions and attack proofs of concept.
Malaysian Reserve
2 days ago
- Malaysian Reserve
Novelis Announces Results of Tender Offer for 3.250% Senior Notes due November 2026
ATLANTA, Aug. 15, 2025 /PRNewswire/ — Novelis Inc. (the 'Company') announced today the results of its indirect wholly-owned subsidiary, Novelis Corporation's (the 'Issuer') previously announced cash tender offer for any and all of its 3.250% Senior Notes due November 2026 (the 'Notes'), upon the terms and conditions included in the Offer to Purchase, dated August 11, 2025. As of the expiration time of the tender offer, which was 5:00 pm., New York City time, on August 15, 2025 (the 'Expiration Time'), the aggregate principal amount of the Notes that have been validly tendered and not validly withdrawn was $738,116,000, representing 98.4% of the $750,000,000 aggregate outstanding principal amount of the Notes, which amount includes $2,326,000 that remain subject to the applicable guaranteed delivery procedures. Holders who indicated by the Expiration Time that they will deliver their Notes through the guaranteed delivery procedures set forth in the Offer to Purchase must deliver their Notes by 5:00 p.m., New York City time, on August 19, 2025. The complete terms and conditions of the Tender Offer were set forth in the Offer to Purchase and the related notice of guaranteed delivery (the 'Notice of Guaranteed Delivery'). Subject to the terms and conditions of the tender offer being satisfied or waived, holders who validly tendered and did not withdraw Notes prior to the Expiration Time will receive the 'Tender Offer Consideration' equal to $997.50 per $1,000 principal amount of Notes. In addition to the Tender Offer Consideration, holders will receive accrued and unpaid interest on the Notes from the most recent payment of semi-annual interest for such Notes preceding the Settlement Date to, but not including, the Settlement Date. The Settlement Date is expected to be August 18, 2025. With respect to the Notes tendered and accepted for purchase, if any, pursuant to the guaranteed delivery procedures described in the Offer to Purchase, the holders of any such Notes will receive payment of the Tender Offer Consideration for such Notes, plus accrued and unpaid interest from the most recent payment of semi-annual interest for such Notes preceding the Settlement Date up to, but not including, the Settlement Date, on the settlement date for any Notes tendered pursuant to a Notice of Guaranteed Delivery, which is expected to be August 20, 2025. All accrued and unpaid interest on the Notes from the most recent payment of semi-annual interest for such Notes up to, but not including, the Settlement Date will cease to accrue on the Settlement Date for all Notes accepted for purchase pursuant to the Tender Offer, including those tendered pursuant to the Notice of Guaranteed Delivery. The Company intends to redeem any Notes that are not purchased in the tender offer in accordance with the indenture governing the Notes as more fully described in the Offer to Purchase. The Company has engaged BNP Paribas Securities Corp. to act as Dealer Manager for the tender offer. Persons with questions regarding the tender offer should contact BNP Paribas Securities Corp. toll-free at (888) 210-4358 or collect at (212) 841-3059. Requests for documents should be directed to D.F. King & Co., Inc., the Tender and Information Agent for the tender offer, at (212) 269-5550 (for banks and brokers) or (800) 967-5071 (for noteholders) or by email at LegalTeamUS@ This press release is for informational purposes only and is not an offer to purchase or a solicitation of an offer to purchase with respect to any of the Notes. The tender offer is being made pursuant to the tender offer documents, including the Offer to Purchase and Notice of Guaranteed Delivery that the Company is distributing to holders of the Notes. The tender offer is not being made to holders of Notes in any jurisdiction in which the making or acceptance thereof would not be in compliance with the securities or other laws of such jurisdiction. None of the Company, the Dealer Manager, the Tender and Information Agent or their respective affiliates is making any recommendation as to whether or not holders should tender all or any portion of their Notes in the tender offer. About Novelis Novelis Inc. is driven by its purpose of shaping a sustainable world together. We are a global leader in the production of innovative aluminum products and solutions and the world's largest recycler of aluminum. Our ambition is to be the leading provider of low-carbon, sustainable aluminum solutions and to achieve a fully circular economy by partnering with our suppliers, as well as our customers in the aerospace, automotive, beverage packaging and specialties industries throughout North America, Europe, Asia and South America. Novelis had net sales of $17.1 billion in fiscal year 2025. Novelis is a subsidiary of Hindalco Industries Limited, an industry leader in aluminum and copper, and the metals flagship company of the Aditya Birla Group, a multinational conglomerate based in Mumbai. For more information, visit Forward-Looking Statements Statements made in this news release which describe Novelis' intentions, expectations, beliefs or predictions may be forward-looking within the meaning of securities laws. Forward-looking statements include statements preceded by, followed by, or including the words 'believes,' 'expects,' 'anticipates,' 'plans,' 'estimates,' 'projects,' 'forecasts,' or similar expressions. Examples of forward-looking statements in this news release are statements about the timing and completion of the tender offer. Novelis cautions that, by their nature, forward-looking statements involve risk and uncertainty and Novelis' actual results could differ materially from those expressed or implied in such statements. Novelis does not intend, and Novelis disclaims any obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.
